Thermo Fisher Scientific Free cash flow decreased by 72.7% to $816.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 126.0%, from $361.00M to $816.00M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows relatively stable performance with a -1.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests strong operational efficiency and the ability to self-fund future innovation or return capital to shareholders, while a decrease may indicate heavy capital expenditure cycles or declining operational profitability.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
High-growth semiconductor and AI infrastructure peers typically prioritize reinvestment, so free cash flow margins are often compared against R&D intensity and capital expenditure requirements of industry rivals.
cf_free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.69B | $2.13B | $1.63B | $1.56B | $1.02B | $1.39B | $2.94B | $271.00M | $1.26B | $2.08B | $3.32B | $904.00M | $1.66B | $1.89B | $2.81B | $361.00M | $1.11B | $1.84B | $2.99B | $816.00M |
| QoQ Change | — | +26.0% | -23.5% | -3.9% | -34.6% | +36.0% | +111.3% | -90.8% | +363.5% | +65.8% | +59.4% | -72.8% | +83.5% | +14.2% | +48.4% | -87.2% | +206.1% | +66.1% | +63.1% | -72.7% |
| YoY Change | — | — | — | — | -39.4% | -34.6% | +80.6% | -82.7% | +22.9% | +49.8% | +13.0% | +233.6% | +32.1% | -9.0% | -15.3% | -60.1% | -33.4% | -3.1% | +6.5% | +126.0% |